India's Pharmaceutical Exports

Country Profile

United States

India's largest pharmaceutical export destination — $15.1 billion in calendar year 2025, accounting for 30.5% of India's total pharma exports.

🇺🇸 #1 Destination · $15.1B · 3.1× growth since 2014
Dual-source profile. Headline figures use US Census import data (calendar year). Category and product detail from DGCIS India export data (fiscal year, Apr–Mar). Both sources shown on trend chart.
$15.1B
Exports CY2025 Census
3.1×
Growth CY2014→2025 Census
30.5%
Share of India Total DGCIS
#1
Rank Among 178 Markets
10.9%
CAGR CY2014→2025 Census
The United States is the world's largest pharmaceutical market and India's top export destination. US Census Bureau data — which records imports as they clear US customs — shows $15.1 billion in Indian pharma imports for calendar year 2025, a 3.1× increase from $4.8 billion in 2014. DGCIS data, which tracks Indian shipments by fiscal year, records $9.4 billion for FY2025–26. The gap reflects methodological differences: Census captures all Indian-origin goods including those transshipped, while DGCIS records direct bilateral shipments.
Export Trend
Census CY DGCIS FY
Category Mix — FY 2025–26 DGCIS
Drug Formulations $8,595M (91.1%) Bulk Drugs / API $550M (5.8%) AYUSH / Herbal $151M (1.6%) Surgicals $128M (1.4%) Vaccines $9M (0.1%)
Top 10 Products (HS8) — FY 2025–26 DGCIS
Indian Pharma Investment in the US Source: RBI ODI Data

Indian pharmaceutical companies have made 491 overseas investment filings into the US — equity, loans, and guarantees — totalling $7.8 billion (2011–2026, RBI records).

$7.8B committed · 491 transactions

2011–2026 · Equity, loans, and guarantees filed with RBI by Indian pharmaceutical companies

Other notable investors:
Aurobindo Pharma · Cipla · Dr Reddy's · Biocon · Strides Pharma · Glenmark · Jubilant Pharma